RET and melanoma: Bevacizumab (anti-VEGF), and lenvatinib (kinase inhibitor of VEGF receptors VEGFR1-3, FGFR1-4, PDGFRα, Kit and RET [36, 37]) had no effect on VM in vitro with our brain tropic human and mouse melanoma cell lines.